全文获取类型
收费全文 | 378575篇 |
免费 | 25038篇 |
国内免费 | 2793篇 |
专业分类
耳鼻咽喉 | 5203篇 |
儿科学 | 8222篇 |
妇产科学 | 10092篇 |
基础医学 | 53068篇 |
口腔科学 | 11800篇 |
临床医学 | 30041篇 |
内科学 | 78215篇 |
皮肤病学 | 8593篇 |
神经病学 | 27379篇 |
特种医学 | 14051篇 |
外国民族医学 | 82篇 |
外科学 | 60586篇 |
综合类 | 9934篇 |
现状与发展 | 1篇 |
一般理论 | 64篇 |
预防医学 | 17391篇 |
眼科学 | 9421篇 |
药学 | 31033篇 |
1篇 | |
中国医学 | 2174篇 |
肿瘤学 | 29055篇 |
出版年
2021年 | 2403篇 |
2019年 | 2741篇 |
2018年 | 4541篇 |
2017年 | 3449篇 |
2016年 | 3538篇 |
2015年 | 4040篇 |
2014年 | 5725篇 |
2013年 | 7420篇 |
2012年 | 10074篇 |
2011年 | 10266篇 |
2010年 | 6222篇 |
2009年 | 5870篇 |
2008年 | 9498篇 |
2007年 | 10354篇 |
2006年 | 10285篇 |
2005年 | 9341篇 |
2004年 | 8883篇 |
2003年 | 8582篇 |
2002年 | 8258篇 |
2001年 | 28343篇 |
2000年 | 28820篇 |
1999年 | 23676篇 |
1998年 | 5057篇 |
1997年 | 4125篇 |
1996年 | 3706篇 |
1995年 | 3503篇 |
1994年 | 3124篇 |
1993年 | 2859篇 |
1992年 | 16093篇 |
1991年 | 14856篇 |
1990年 | 14189篇 |
1989年 | 13992篇 |
1988年 | 12620篇 |
1987年 | 12090篇 |
1986年 | 11147篇 |
1985年 | 10365篇 |
1984年 | 6940篇 |
1983年 | 5629篇 |
1982年 | 2730篇 |
1979年 | 5490篇 |
1978年 | 3354篇 |
1977年 | 2970篇 |
1975年 | 2639篇 |
1974年 | 3072篇 |
1973年 | 2871篇 |
1972年 | 2835篇 |
1971年 | 2786篇 |
1970年 | 2516篇 |
1969年 | 2553篇 |
1968年 | 2259篇 |
排序方式: 共有10000条查询结果,搜索用时 312 毫秒
41.
Ingigerður S. Sverrisdóttir Sigrún H. Lund Ingemar Turesson Magnus Björkholm Lynn R. Goldin Ola Landgren Sigurður Y. Kristinsson 《British journal of haematology》2019,186(1):37-44
Parental longevity is associated with an increased life expectancy; results with regard to specific diseases are conflicting. There are limited data focusing on host characteristics and their effect on survival among multiple myeloma (MM) patients and individuals with monoclonal gammopathy of undetermined significance (MGUS). Therefore, our aim was to evaluate the impact of parental longevity on survival of patients with MM and MGUS. A total of 4675 patients with MM, 6812 MGUS patients and 13 398 population-based controls for MM as well as 19 110 controls for MGUS, from 1988 to 2013, were included in the study. Longevity was defined as >90 years of age. Among MM patients, parental longevity was associated with a decreased risk of death [hazard ratio (HR) = 0·92, 95% confidence interval (CI) 0·84–0·99] and the same was true for MGUS patients (HR = 0·87, 95% CI 0·78–0·96). Having one long lived parent significantly decreased the risk of death in both groups, but was not statistically significant when both parents exceeded 90 years of age. In conclusion, parental longevity decreases the risk of death for patients with MM and MGUS which may reflect the importance of the host's genetic and environmental factors in relation to survival. 相似文献
42.
W. Gao W. Cao J. Lv C. Yu T. Wu S. Wang L. Meng D. Wang Z. Wang Z. Pang M. Yu H. Wang X. Wu Z. Dong F. Wu G. Jiang X. Wang Y. Liu J. Deng L. Lu L. Li 《Journal of internal medicine》2019,286(3):299-308
The Chinese National Twin Registry (CNTR) currently includes data from 61 566 twin pair from 11 provinces or cities in China. Of these, 31 705, 15 060 and 13 531 pairs are monozygotic, same‐sex dizygotic and opposite‐sex dizygotic pairs, respectively, determined by opposite sex or intrapair similarity. Since its establishment in 2001, the CNTR has provided an important resource for analysing genetic and environmental influences on chronic diseases especially cardiovascular diseases. Recently, the CNTR has focused on collecting biologic specimens from disease‐concordant or disease‐discordant twin pairs or from twin pairs reared apart. More than 8000 pairs of these twins have been registered, and blood samples have been collected from more than 1500 pairs. In this review, we summarize the main findings from univariate and multivariate genetic effects analyses, gene–environment interaction studies, omics studies exploring DNA methylation and metabolomic markers associated with phenotypes. There remains further scope for CNTR research and data mining. The plan for future development of the CNTR is described. The CNTR welcomes worldwide collaboration. 相似文献
43.
Inna Y. Gong Nigel S. Tan Sammy H. Ali Gerald Lebovic Muhammad Mamdani Shaun G. Goodman Dennis T. Ko Andreas Laupacis Andrew T. Yan 《The Canadian journal of cardiology》2019,35(5):653-660
Background
Although it is known that women do not participate in trials as frequently as men, there are limited recent data examining how women recruitment has changed over time.Methods
We conducted MEDLINE search using a validated strategy for randomized trials published in New England Journal of Medicine, Lancet, and Journal of the American Medical Association between 1986 and 2015, and included trials evaluating pharmacologic or nonpharmacologic therapies. We abstracted data on demographics, intervention type, clinical indication, and trial design characteristics, and examined their relationships with women enrollment.Results
In total, 598 trials met inclusion criteria. Women enrollment increased significantly over time (21% between 1986 and 1990 to 33% between 2011 and 2015; Pfor trend < 0.001) and did not differ by journal or funding source. Women enrollment varied with clinical indication, comprising 37% for non–coronary artery disease vascular trials, 30% for coronary artery disease trials, 28% for heart failure trials, and 28% for arrhythmia trials (P < 0.001), which were all significantly lower than the expected proportion in disease populations (P < 0.001). Women enrollment varied with trial type (31%, 29%, and 26% for pharmacologic, device, and procedural trials, respectively; P = 0.001). These findings were corroborated using multivariable analysis. We found significant positive correlations between women enrolled, and mean age and total number of participants. Fewer women were enrolled in trials reporting statistically significant results than those who did not (P = 0.001).Conclusions
Although enrollment of women has increased over time, it remains lower than the relative proportion in the disease population. Future studies should elucidate the reasons for persistent under-representation of women in clinical trials. 相似文献44.
45.
46.
47.
48.
Carlo Ammendolia Y. Raja Rampersaud Danielle Southerst Aksa Ahmed Michael Schneider Gillian Hawker Claire Bombardier Pierre Côté 《The spine journal》2019,19(3):386-394
BACKGROUND CONTEXT
Lumbar spinal stenosis (LSS) can impair blood flow to the spinal nerves giving rise to neurogenic claudication and limited walking ability. Reducing lumbar lordosis can increases the volume of the spinal canal and reduce neuroischemia. We developed a prototype LSS belt aimed at reducing lumbar lordosis while walking.PURPOSE
The aim of this study was to assess the short-term effectiveness of a prototype LSS belt compared to a lumbar support in improving walking ability in patients with degenerative LSS.STUDY DESIGN
This was a two-arm, double-blinded (participant and assessor) randomized controlled trial.PATIENT SAMPLE
We recruited 104 participants aged 50 years or older with neurogenic claudication, imaging confirmed degenerative LSS, and limited walking ability.OUTCOME MEASURES
The primary measure was walking distance measured by the self-paced walking test (SPWT) and the primary outcome was the difference in proportions among participants in both groups who achieved at least a 30% improvement in walking distance from baseline using relative risk with 95% confidence intervals.METHODS
Within 1 week of a baseline SPWT, participants randomized to the prototype LSS belt group (n=52) and those randomized to the lumbar support group (n=52) performed a SPWT that was conducted by a blinded assessor. The Arthritis Society funded this study ($365,000 CAN) with salary support for principal investigator funded by the Canadian Chiropractic Research Foundation ($500,000 CAN for 5 years).RESULTS
Both groups showed significant improvement in walking distance, but there was no significant difference between groups. The mean group difference in walking distance was ?74 m (95% CI: ?282.8 to 134.8, p=.49). In total, 62% of participants wearing the prototype LSS belt and 82% of participants wearing the lumbar support achieved at least 30% improvement in walking distance (relative risk, 0.7; 95% CI: 0.5–1.3, p=.43).CONCLUSIONS
A prototype LSS belt demonstrated significant improvement in walking ability in degenerative LSS but was no better than a lumbar support. 相似文献49.
50.
Fahad A. Bashiri Hissah K. Al Abdulsalam Saeed M. Hassan Waleed A. Al Twaijri Fuad I. Almalki Amal Y. Kentab Muddathir H. Hamad Ali H. Alwadei Daniah A. Al-Showaeir Ikhlass S. Altweijri Haifa M. Aldabjan Moudi S. Aldegether Abdulrahman A. Albakr Wajda M. Alhothali Abdulrazag M. Ajlan Hamdy H. Hassan Mustafa A. Salih 《Neurosciences (Riyadh, Saudi Arabia)》2019,24(4):257
Objectives:To review the experience of 2 tertiary centers in Saudi Arabia with intracranial hypertension (IH) in the pediatric population.Methods:We retrospectively reviewed and analyzed pediatric patients diagnosed with IH from June 2002 to May 2017 in 2 institutes.Results:We identified 53 patients (30 females and 23 males) with a mean age of 7 years at the time of presentation. Among them, 41 patients were younger than 12 years, and 12 were older. Obese and overweight patients constituted 27.00% (n = 14) of all cases, 8 (66.7%) of whom were older than 12 years. The most common presenting feature was papilledema followed by headache. Vitamin D deficiency, which constituted the most common associated condition, was identified in 12 (22.6%) patients. Acetazolamide was the treatment option in 98.11% of patients, and only 5.7% underwent surgical interventions. The length of follow-up ranged from 6 months to 8 years.Conclusion:Intracranial hypertension is rare in children and commonly seen in overweight females older than 12 years similar to adults. Patients younger than 12 years tend to develop secondary IH. More studies are needed to characterize the clinical presentation and guide the management plan.Intracranial hypertension (IH) is rarely reported in children. It is characterized by increased intracranial pressure (ICP) without any evidence of underlying brain pathology, structural abnormalities, hydrocephalus, or any abnormal meningeal enhancement.1 The incidence of IH differs from region to region due to variations in the prevalence of obesity and other secondary causes. The annual incidence of IH in children is 0.9 per 100,000 in the United States,2 0.5 per 100,000 in Germany,3 0.6 per 100,000 in Nova Scotia and Prince Edward Island in Eastern Canada,4 and 1.2 per 100,000 in Croatia.5 A study carried out in Oman estimated the incidence of IH to be 1.9 per 100,000 in children below 15 years of age; with it being higher in female children.6 The present study aimed to review the clinical presentation, possible aetiological factors, diagnosis, management, and outcomes in children with IH in 2 tertiary institutes in Saudi Arabia. 相似文献